Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain

Conclusion Early treatment with IFNβ-1b after a CIS vs. delayed treatment is efficient from a social perspective, but it may not be efficient from the perspective of the NHS which does not take non health-related costs into account.
Source: Neurologia - Category: Neurology Source Type: research